Equity strategies

Carmignac Portfolio Grandchildren

Luxembourg SICAV sub-fundGlobal marketArticle 9
Share Class

LU2420652476

An intergenerational Fund focused on quality, sustainable companies
  • A Fund focused on selecting high-quality companies around the world, with sound financials and sustainable profitability.
  • An investment process based on rigorous fundamental analysis, quantitative screening, and a socially responsible investment approach.
  • A concentrated, low turnover portfolio of high-conviction names seeking to provide steady growth of your capital over the long term.
Key documents
Asset Allocation
Equities90.4 %
Other9.6 %
Data as of:  Sep 30, 2025.
Risk Indicator

1

2

3

4

5

6

7

Lowest risk Highest risk
Recommended Minimum Investment Horizon
5 years
Cumulative Performance since launch
+ 9.8 %
-
-
+ 45.3 %
- 3.9 %
From 31/12/2021
To 06/11/2025
Calendar Year Performance 2024
-
-
-
-
-
-
-
- 23.7 %
+ 23.8 %
+ 22.7 %
Net Asset Value
109.81 €
Asset Under Management
441 M €
Net Equity Exposure30/09/2025
90.4 %
SFDR - Fund Classification

Article

9
Data as of:  Nov 6, 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.

Carmignac Portfolio Grandchildren fund performance

Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.

Our monthly comments

Data as of:  Oct 31, 2025.
Fund management team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
[Management Team] [Author] Ejikeme Obe

Obe Ejikeme

Fund Manager, Analyst

Market environment

  • Global equities rose 4.1% (EUR) in October, led by a narrow group of AI-driven growth stocks, while defensive names lagged.
  • Gains were supported by easing US–China trade tensions and a solid US earnings season, with 82% of companies beating expectations.
  • In the U.S., economic activity remains strong, with leading indicators still in expansion territory. Despite the data gap caused by the shutdown, inflation re-accelerated in September, again exceeding the 3%-mark year-on-year.
  • As expected, the Fed cut rates by 25 bps to a 3.75–4.00% range, keeping a supportive stance while remaining cautious on further easing.
  • In the euro area, activity indicators improved, with both composite and services PMIs returning to expansion territory, driven by a rebound in Germany. Q3 GDP rose +0.2%, slightly above expectations.
  • Japan outperformed, buoyed by pro-Abenomics policies from new PM Sanae Takaichi and a weaker yen aiding exporters.
  • Emerging markets (+6.1%) advanced, led by Korea and Taiwan on positive trade developments with China and semiconductor strength.
  • The S&P 500 gained 4.1%, recovering from trade-driven volatility as strong earnings and AI optimism lifted sentiment.
  • European equities trailed peers amid French political noise and lower AI exposure, though autos and luxury goods gained on improving Chinese demand.

Performance commentary

  • In October, the Fund delivered a positive absolute performance, though it lagged its reference indicator.
  • The relative underperformance was mainly driven by the technology sector.
  • Our underweight exposure to technology weighed on relative returns, as the benchmark was led by an increasingly narrow group of AI-related stocks.
  • Although we hold significant investments in this area with Nvidia, Alphabet, and ASML among our top contributors during the month, these exposures were not sufficient to match the benchmark’s strength.
  • Our financial holdings also detracted from performance. ICE and UBS declined over the period; however, we believe these names are oversold and modestly increased our positions.
  • Conversely, after several months of weakness, our healthcare holdings contributed positively. Thermo Fisher, Vertex, and Eli Lilly reported strong results, supported by sustained demand and resilient margins, helping to restore investor confidence in the sector.

Outlook strategy

  • Our macroeconomic framework continues to advocate a defensive positioning, as valuation remains a key concern at the overall market level.
  • During the month, we made several portfolio adjustments. We initiated a new position in Capgemini, viewed as an attractive and inexpensive hedge against fears of AI-driven disruption, trading at around 10x earnings, and we continued to build our position in DSV.
  • Over the period, we trimmed positions in Industrials such as Prysmian and Schneider, following their strong performance in recent months.
  • However, we took advantage of the market weakness at month-end to re-add exposure to Prysmian and Schneider, recognizing their potential as key beneficiaries of ongoing developments related to artificial intelligence.
  • Several areas of the portfolio that had recently underperformed are now presenting attractive opportunities for long-term investors, and we used this opportunity to increase our allocations.
  • This was particularly the case within Financials, where stocks such as S&P Global and Mastercard have underperformed due to unfounded concerns around AI-related disruption, and within Consumer Staples, where names like P&G and Unilever have, in our view, lagged unjustly.
  • In the current environment, earnings visibility is likely to be increasingly rewarded. We therefore maintain a disciplined stance, limiting exposure to cyclical sectors in favour of quality.
  • High-quality companies continue to trade at multi-year relative lows despite record earnings, offering a rare entry point for long-term investors.

Performance Overview

Data as of:  Nov 6, 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
Source: Carmignac at 08/11/2025

Carmignac Portfolio Grandchildren Portfolio overview

Below is an overview of the composition of the portfolio.

Geographical Breakdown

Data as of:  Sep 30, 2025.
North America63.6 %
Europe36.4 %
View details

Key figures

Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.

Exposure Data

Data as of:  Sep 30, 2025.
Equity Investment Weight90.4 %
Net Equity Exposure90.4 %
Number of Equity Issuers41
Active Share80.0 %

The strategy in a nutshell

Discover the Fund’s main features and benefits through the words of the Fund Managers.
Fund Management Team
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
[Management Team] [Author] Ejikeme Obe

Obe Ejikeme

Fund Manager, Analyst
Carmignac Portfolio Grandchildren is an intergenerational Fund that focuses on high-quality companies to help investors build capital not only for themselves, but also for future generations.
[Management Team] [Author] Denham Mark

Mark Denham

Head of Equities, Fund Manager
View Fund's characteristics

Articles that may interest you

Strategies insightsOctober 16, 2025English

Carmignac Portfolio Grandchildren: Letter from the Fund Managers - Q3 2025

3 minute(s) read
Find out more
Strategies insightsJuly 14, 2025English

Carmignac Portfolio Grandchildren: Letter from the Fund Managers - Q2 2025

3 minute(s) read
Find out more
Strategies insightsApril 16, 2025English

Quality: your compass in an uncertain world

Find out more
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
​The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performance is shown net of fees (excluding any subscription fees payable to the distributor). Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.